Autolus Therapeutics Soars 10.27% on Encouraging FELIX Study Data

On June 12, 2025, Autolus Therapeutics' stock surged by 10.27% in pre-market trading, reflecting significant investor interest and optimism surrounding the company's recent developments.

Autolus Therapeutics presented updated long-term data from the FELIX study of obecabtagene autoleucel (obe-cel) at the European Hematology Association (EHA) Congress. The data showed a median duration of response of 42.6 months, with more than half of the patients still in remission at 24 months. Notably, 38% of ongoing responders did not receive any subsequent therapy by month 33, suggesting that a proportion of patients with relapsed/refractory (r/r) B-ALL may not need further therapy following treatment with obe-cel.

Dr. Christian Itin, Chief Executive Officer of Autolus, highlighted the durability of response without any subsequent therapy in two out of every five responders as a key factor in transforming therapy for adult r/r B-ALL patients. The long-term plateau observed at the last data cut was encouraging, indicating a well-tolerated, effective, and durable treatment option for patients who often have a poor prognosis and have had multiple prior treatments.

The study also presented findings on the efficacy and safety outcomes of obe-cel stratified by age, showing that the treatment was associated with deep and durable remissions resulting in favorable overall remission rates, event-free survival, and overall survival with a low incidence of Grade ≥3 CRS and ICANS in both age groups (<55 years and ≥55 years). These findings indicate that obe-cel is effective and has a positive benefit and risk profile regardless of patient age, including in older adults with r/r B-ALL.